Cerebrolysin

Yari-Ilkhchi A, et al. Nanoscale Advances, 2024, 6(3), 990-1000.

Cerebrolysin (CRL) was successfully immobilized onto graphene oxide (GO) to develop a novel drug delivery system with controlled release properties. The GO-CRL composite was prepared by dispersing 70 mg of CRL in 40 mL of a GO aqueous suspension (1 mg/mL) and stirring the mixture at 20°C for 24 hours. The resulting complex was purified via centrifugation at 10,000 rpm, followed by filtration and deionized water washing to remove unbound CRL. The final product was vacuum-dried at room temperature.
The drug release profile of CRL from the GO-CRL system was investigated under physiological conditions (PBS, pH 7.4, 37°C) over 14 days using a dialysis bag setup. Supernatants collected at defined intervals were analyzed spectrophotometrically to quantify CRL release. The results demonstrated a sustained release pattern, highlighting the potential of GO as an efficient carrier for CRL delivery.

Martínez-Torres NI, et al. Neuroscience, 2024, 549, 76-83.

Cerebrolysin (CBL) has demonstrated significant efficacy in promoting recovery following stroke when administered alone or in combination with nicotinamide (NAM). In a rat model of permanent middle cerebral artery occlusion (pMCAO), four treatment groups were studied: saline, CBL, NAM, and CBL-NAM combination. CBL (2.5 mL/kg) and NAM (500 mg/kg) were administered immediately after surgery and at subsequent intervals of 24, 48, and 72 hours.
The combined CBL-NAM treatment showed synergistic effects, including reduced infarct size, enhanced cognitive performance (evaluated via the novel object recognition test), and increased brain-derived neurotrophic factor (BDNF) levels near the infarct zone. Furthermore, Sholl analysis revealed greater dendritic complexity in CA1 hippocampal pyramidal neurons with the combination therapy compared to single-agent treatments. These findings underscore Cerebrolysin's potential to enhance neuroplasticity and cognitive recovery when used in conjunction with complementary agents like NAM.

Abdelaty AO, et al. Journal of Psychiatric Research, 2024, 172, 171-180.

Cerebrolysin demonstrates significant therapeutic potential when combined with lithium in treating depression. This study explored the neurochemical, behavioral, and histopathological effects of lithium augmentation with Cerebrolysin in a reserpine-induced rat model of depression.
Reserpine administration caused marked depressive-like behavior, oxidative stress, altered acetylcholinesterase activity, reduced monoamine levels in the cortex and hippocampus, and decreased brain-derived neurotrophic factor (BDNF). Treatment with Cerebrolysin (2.5 mL/kg) or lithium alone partially reversed these deficits. However, their combination yielded superior therapeutic outcomes, effectively normalizing behavior, oxidative stress markers, and neurochemical parameters. Histopathological analysis further confirmed significant restoration of brain structure with the combined therapy. The synergistic effects of Cerebrolysin and lithium suggest their potential as an effective combination therapy for managing treatment-resistant depression.